Catalogo Ricerca UNIKORE

Catalogo Ricerca UNIKORE: [18541] Home page macrotipologia

Sfoglia

1 Contributo su Rivista 10715
- 1.1 Articolo in rivista 10192
- 1.2 Recensione in rivista 287
- 1.3 Scheda bibliografica 12
- 1.4 Nota a sentenza 97
- 1.5 Abstract in rivista 122
- 1.6 Traduzione in rivista 5

2 Contributo in Volume 3123
- 2.1 Contributo in volume (Capitolo o Saggio) 2742
- 2.2 Prefazione/Postfazione 139
- 2.3 Breve introduzione 45
- 2.4 Voce (in dizionario o enciclopedia) 87
- 2.5 Traduzione in volume 27
- 2.6 Recensione in volume 62
- 2.7 Schede di catalogo 21

3 Libro 733
- 3.1 Monografia o trattato scientifico 680
- 3.2 Concordanza 1
- 3.3 Indice 1
- 3.4 Bibliografia 3
- 3.5 Edizione critica 13
- 3.6 Pubblicazione di fonti inedite 8
- 3.7 Commento scientifico 13
- 3.8 Traduzione di libro 14

4 Contributo in Atti di Convegno (Proceeding) 3310
- 4.1 Contributo in Atti di convegno 2456
- 4.2 Abstract in Atti di convegno 687
- 4.3 Poster 167

5 Altro 398
- 5.01 Composizione 7
- 5.02 Disegno 89
- 5.03 Design 1
- 5.04 Performance 3
- 5.05 Esposizione 4
- 5.06 Mostra 23
- 5.07 Manufatto 49
- 5.08 Prototipo d'arte e relativi progetti 2
- 5.09 Cartografia 23
- 5.10 Banca dati 2
- 5.11 Software 6
- 5.12 Altro 189

6 Brevetti 8
- 6.1 Brevetto 8

7 Curatele 254
- 7.1 Curatela 254

Prodotti recenti

Significant Advancements and Evolutions in Chimeric Antigen Receptor Design

: Recent times have witnessed remarkable progress in cancer immunotherapy, drastically changing the cancer treatment landscape. Among the various immunotherapeutic approaches, adoptive cell therapy (ACT), particularly chimeric antigen receptor (CAR) T cell therapy, has emerged as a promising strategy to tackle cancer. CAR-T cells are genetically engineered T cells with synthetic receptors capable of recognising and targeting tumour-specific or tumour-associated antigens. By leveraging the int...

Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?

The coronavirus disease 2019 (COVID‐19) is currently representing a global health threat especially for fragile individuals, such as cancer patients. It was demonstrated that cancer patients have an increased risk of developing a worse symptomatology upon severe acute respiratory syndrome associated coronavirus‐2 (SARS‐CoV‐2) infection, often leading to hospitalization and intensive care. The consequences of this pandemic for oncology are really heavy, as the entire healthcare system got reor...

Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review)

The severe acute respiratory syndrome associated coronavirus-2 (SARS-CoV-2) poses a threat to human life worldwide. Since early March, 2020, coronavirus disease 2019 (COVID-19), characterized by an acute and often severe form of pneumonia, has been declared a pandemic. This has led to a boom in biomedical research studies at all stages of the pipeline, from the in vitro to the clinical phase. In line with this global effort, known drugs, currently used for the treatment of other pathologies, ...

Quality of Life in Women Diagnosed with Breast Cancer after a 12-Month Treatment of Lifestyle Modifications

Healthy lifestyles are associated with better health-related quality of life (HRQoL), favorable prognosis and lower mortality in breast cancer (BC) survivors. We investigated changes in HRQoL after a 12-month lifestyle modification program in 227 BC survivors participating in DEDiCa trial (Mediterranean diet, exercise, vitamin D). HRQoL was evaluated through validated questionnaires: EQ-5D-3L, EORTC-QLQ-C30 and EORTC QLQ-BR23. Baseline changes were tested using analysis of variance. Multiple ...

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

Background: Reliable and affordable prognostic and predictive biomarkers for urothelial carcinoma treated with immunotherapy may allow patients' outcome stratification and drive therapeutic options. The SAUL trial investigated the safety and efficacy of atezolizumab in a real-world setting on 1004 patients with locally advanced or metastatic urothelial carcinoma who progressed to one to three prior systemic therapies. Patients and methods: Using the SAUL Italian cohort of 267 patients, we inv...

Scopri

Accesso al fulltext

no fulltext18539